Abstract:Abstract Cancer is a leading cause of human death worldwide. Commonly used methods of treatment such as surgery, radiation and chemotherapy tend to be largely successful but are extremely invasive and have serious toxic side effects. The possibility of manipulating viral genomes and the natural ability of viruses to efficiently infect various cell types has increased an interest in using a virus-based delivery system to express cytotoxic products within target cells. Thus, oncolytic viruses represent an attractive alternative to currently used anti-cancer treatments. Among different viral methods for gene delivery, vectors based on a human parvovirus, the adeno-associated virus (AAV) has attracted much attention mainly because of its non-pathogenic nature, and its ability to mediate long-term, sustained therapeutic gene expression. In current studies identified AAV serotype 6 being particularly effective in transduction of several human prostate (PC3), breast (T47D) and liver (Huh7) cancer cell in vitro. We also found that transduction efficiency of these vectors can be significantly, up to 3-5-fold, improved by site-direct mutagenesis of surface exposed residues involved in intracellular trafficking. Over thirty single tyrosine (Y), serine (S), threonine (T) and multiple capsid mutants were developed and AAV6-Y705-731F+T492V was identified the most efficient. However, the vector promiscuity makes it difficult to use in vivo. In the more recent studies on AAV crystal structure, combined with various site-directed and insertion mutagenesis studies of the capsid gene, have identified specific regions of the capsid proteins that are surface-exposed and tolerant to insertion of the peptides. In the current studies, we developed novel AAV-based vectors for targeting of human cancer cells by incorporating Arg-Gly-Asp (RGD) containing peptide to enable AAV to infect integrin-expressing cells. These AAV6-RGD vectors improve transduction efficiency for approximately 3-fold compare with wild-type AAV6 vectors by enhancing viral entry to the cells. Combination of RGD-peptide and mutations of surface-exposed residues on a single AAV6 capsid further increases transduction efficiency up to approximately 8-10-fold. We also introduced additional mutation at lysine (K531E) since this was shown to impart a heparan sulfate proteoglycan binding ability of vectors and, thus, decrease affinity to mice hepatocytes. We are currently conducting studies on xenograft animal model in immune-deficient mice to prove specificity and high transduction efficiency of human cancer cells by AAV6-RGD-Y705-731F+T492V-K531E vectors in vivo. In summary, this approach potentially can lead to the development of therapeutic AAV vectors with selective tropism to human cancer cells. Citation Format: Rana Sayroo, Zifei Yin, Diego Nolasco, Munjal Pandya, Chen Ling, George Aslanidi. Development of the novel AAV-based vectors with selective tropism to human cancer cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3534. doi:10.1158/1538-7445.AM2015-3534

Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Adeno-associated Virus-Mediated Cancer Gene Therapy: Current Status.

Adeno-associated virus vector as a platform for gene therapy delivery

Adeno-associated virus as a delivery vector for gene therapy of human diseases

Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).

Adeno-Associated Virus (AAV) as a Vector for Gene Therapy

Engineering adeno-associated virus vectors for gene therapy

Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions

Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies

Generation of targeted adeno-associated virus (AAV) vectors for human gene therapy.

The clinical landscape for AAV gene therapies

Adeno-associated virus therapies: Pioneering solutions for human genetic diseases

Optimization strategies and advances in the research and development of AAV‐based gene therapy to deliver large transgenes

Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma

Abstract 3534: Development of the Novel AAV-based Vectors with Selective Tropism to Human Cancer Cells

Clinical Pharmacology Perspective on Development of Adeno‐Associated Virus Vector‐Based Retina Gene Therapy

Adeno-Associated Virus Vectors-a Target of Cellular and Humoral Immunity-are Expanding Their Reach Toward Hematopoietic Stem Cell Modification and Immunotherapies

Adeno-Associated Virus Engineering and Load Strategy for Tropism Modification, Immune Evasion and Enhanced Transgene Expression

Adeno-associated viral vectors for correction of inborn errors of metabolism: progressing towards clinical application.

Understanding AAV vector immunogenicity: from particle to patient